[2] Bacqueville, D., Jacques, C., Duprat, L., Jamin, E.L., Guiraud, B., Perdu, E., Bessou-Touya, S., Zalko, D., Duplan, H
Take together: They recycle each other to stay active longer
Whilst several peptidesparticularly GLP-1 receptor agonists such as semaglutide and liraglutideshow promise in research settings for reducing liver fat, none are currently licensed by the MHRA specifically for treating fatty liver disease
doi: 10.1093/mtomcs/mfab058
NAPRA National Association of Pharmacy Regulatory Authorities: Compounding Standards: Canadian standards for pharmacy compounding
These foods are generally well-tolerated by GLP-1 users and can be introduced gradually to minimise digestive discomfort